PMID- 31653191
OWN - NLM
STAT- MEDLINE
DCOM- 20200402
LR  - 20200402
IS  - 1477-0962 (Electronic)
IS  - 0961-2033 (Linking)
VI  - 28
IP  - 13
DP  - 2019 Nov
TI  - Treatment with intravenous immunoglobulins in systemic lupus erythematosus: a 
      single-center experience with 63 patients.
PG  - 1566-1570
LID - 10.1177/0961203319883680 [doi]
AB  - BACKGROUND: Intravenous immunoglobulin (IVIG) is prepared using purified human 
      plasma. IVIG therapy has immunomodulatory effects on autoimmune diseases, 
      including severe systemic lupus erythematosus (SLE). However, reports of its 
      effects on large cohorts are scarce. METHODS: This single-center retrospective 
      study included SLE patients treated with at least one IVIG cycle for SLE 
      complications. Demographic data, indications, cycle numbers, and clinical 
      improvement with IVIG were evaluated. SLE Disease Activity Index 2000 (SLEDAI-2K) 
      scores were calculated at admission and after IVIG treatment in order to measure 
      clinical improvement. RESULTS: Sixty-three SLE patients treated with IVIG (median 
      age: 29 years; interquartile range 21-36 years; 84.13% female) were included, who 
      received 2 g/kg IVIG for two to five days. Main indications were immune 
      thrombocytopenia, hypogammaglobulinemia, infection during a SLE flare, 
      bicytopenia, and immune hemolytic anemia. Seven patients received more than one 
      IVIG cycle without severe adverse effects. Significant differences were found in 
      SLEDAI-2K scores when the indications were immune thrombocytopenia and 
      hypogammaglobulinemia, with a trend for hemolytic anemia. Patients with 
      concomitant infection, myopathy, and gastrointestinal involvement showed a 
      considerable reduction in their last SLEDAI-2K scores. Fourteen patients died 
      during hospitalization, mainly due to septic shock and active SLE. CONCLUSIONS: 
      IVIG showed adequate tolerance and effectiveness in selected severe SLE 
      manifestations, mainly hematological involvement. It was useful for concomitant 
      infection.
FAU - Nieto-Aristizabal, I
AU  - Nieto-Aristizabal I
AD  - Grupo de Investigacion en Reumatologia, Autoinmunidad y Medicina Traslacional 
      (GIRAT), Universidad Icesi, Fundacion Valle del Lili, Cali, Colombia.
FAU - Martinez, T
AU  - Martinez T
AD  - Grupo de Investigacion en Reumatologia, Autoinmunidad y Medicina Traslacional 
      (GIRAT), Universidad Icesi, Fundacion Valle del Lili, Cali, Colombia.
AD  - Medical School, Universidad Icesi, Cali, Colombia.
FAU - Urbano, M-A
AU  - Urbano MA
AD  - Grupo de Investigacion en Reumatologia, Autoinmunidad y Medicina Traslacional 
      (GIRAT), Universidad Icesi, Fundacion Valle del Lili, Cali, Colombia.
AD  - Medical School, Universidad Icesi, Cali, Colombia.
FAU - Posso-Osorio, I
AU  - Posso-Osorio I
AD  - Grupo de Investigacion en Reumatologia, Autoinmunidad y Medicina Traslacional 
      (GIRAT), Universidad Icesi, Fundacion Valle del Lili, Cali, Colombia.
FAU - Plata, I F
AU  - Plata IF
AD  - Medical School, Universidad Icesi, Cali, Colombia.
FAU - Garcia-Robledo, J E
AU  - Garcia-Robledo JE
AD  - Grupo de Investigacion en Reumatologia, Autoinmunidad y Medicina Traslacional 
      (GIRAT), Universidad Icesi, Fundacion Valle del Lili, Cali, Colombia.
FAU - Aragon, C C
AU  - Aragon CC
AD  - Grupo de Investigacion en Reumatologia, Autoinmunidad y Medicina Traslacional 
      (GIRAT), Universidad Icesi, Fundacion Valle del Lili, Cali, Colombia.
FAU - Santos, V A
AU  - Santos VA
AD  - Grupo de Investigacion en Reumatologia, Autoinmunidad y Medicina Traslacional 
      (GIRAT), Universidad Icesi, Fundacion Valle del Lili, Cali, Colombia.
AD  - Medical School, Universidad Icesi, Cali, Colombia.
FAU - Tobon, G J
AU  - Tobon GJ
AUID- ORCID: 0000-0002-6031-4218
AD  - Grupo de Investigacion en Reumatologia, Autoinmunidad y Medicina Traslacional 
      (GIRAT), Universidad Icesi, Fundacion Valle del Lili, Cali, Colombia.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20191025
PL  - England
TA  - Lupus
JT  - Lupus
JID - 9204265
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Immunologic Factors)
SB  - IM
MH  - Adult
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Immunoglobulins, Intravenous/*administration & dosage/adverse effects
MH  - Immunologic Factors/*administration & dosage/adverse effects
MH  - Lupus Erythematosus, Systemic/complications/*drug therapy/physiopathology
MH  - Male
MH  - Retrospective Studies
MH  - Severity of Illness Index
MH  - Treatment Outcome
MH  - Young Adult
OTO - NOTNLM
OT  - Intravenous immunoglobulins
OT  - SLEDAI
OT  - immune thrombocytopenia
OT  - infection
OT  - systemic lupus erythematosus
EDAT- 2019/10/28 06:00
MHDA- 2020/04/03 06:00
CRDT- 2019/10/27 06:00
PHST- 2019/10/28 06:00 [pubmed]
PHST- 2020/04/03 06:00 [medline]
PHST- 2019/10/27 06:00 [entrez]
AID - 10.1177/0961203319883680 [doi]
PST - ppublish
SO  - Lupus. 2019 Nov;28(13):1566-1570. doi: 10.1177/0961203319883680. Epub 2019 Oct 
      25.